-
Mashup Score: 6
As the number of physician-scientists continues to decline, action must be taken to support them as they embark on their careers.
Source: Science Translational MedicineCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0HRB investment of €21 million in cancer clinical trials will transform cancer care in Ireland - 3 year(s) ago
The funding will tackle childhood and adult cancers, making a real difference to the lives of cancer patients, allowing them more access to cancer trials by increasing the resources and expertise required to conduct them.
Source: www.hrb.ieCategories: Latest Headlines, Oncologists1Tweet-
https://t.co/dCo8Re3vEb
-
https://t.co/dCo8Re3vEb
-
-
Mashup Score: 0Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) | OncologyPRO - 3 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Latest Headlines, Oncologists1Tweet-
https://t.co/ntpX4nezgM @RoussosTorres @NCICTEP_ClinRes @hopkinskimmel
-
-
Mashup Score: 1A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer - PubMed - 3 year(s) ago
Immune checkpoint inhibitors produce modest responses in metastatic breast cancer, however, combination approaches may improve responses. A single arm pilot study was designed to determine the overall response rate (ORR) of durvalumab and tremelimumab, and evaluate immunogenomic dynamics in metastat …
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet-
https://t.co/TBPjnQypHw
-
-
Mashup Score: 1Dr. Vered Stearns, oncologist at Johns Hopkins, is on the cutting edge of breast cancer research - 4 year(s) ago
Dr. Vered Stearns is considered one of Johns Hopkins’ top experts in breast cancer, serving in a variety of roles.
Source: Baltimore Jewish TimesCategories: Latest Headlines, Oncologists1Tweet-
Great article about my amazing mentor @VeredStearns @hopkinskimmel and the role of clinical/translational researchers in moving the field forward. https://t.co/5rD5YbjgQV
-
-
Mashup Score: 1‘Negative’ Oncology Results May Miss Endpoints, But Not Lessons. Here's Why They're of Value - 4 year(s) ago
Hematology/oncology fellows repeatedly have two lessons hammered into their heads, particularly if they train at academic institutions.
Source: ASCO Daily NewsCategories: Latest Headlines, Oncologists1Tweet-
‘Negative’ Oncology Results: “As investigators, we must do our best to keep our promise to those participants and the cancer community as a whole by sharing any and all knowledge gained.” https://t.co/I80cvOsk8q
-
-
Mashup Score: 3Women Who Conquer Cancer: Dr. Jennifer A. Ligibel Believes Mentorship Is a Key Piece to Leveling the Playing Field - 4 year(s) ago
2021 Hologic, Inc Endowed Women Who Conquer Cancer (WWCC) Mentorship Award recipient, Dr. Jennifer A. Ligibel, understands that mentoring is critical in developing the next generation of scientists.
Source: ASCO ConnectionCategories: Latest Headlines, Oncologists1Tweet-
Great @ASCO article on #Mentorship and #WomenInMedicine #WomenInSTEM #WomenInOncology https://t.co/buAU4fubFv @UCCMedHealth @CanResUCC @CancerTrialCork @cancertrials_ie @AlCRIproject @IrishLungCancer @IrishCancerSoc @BreakthroCancer
-
-
Mashup Score: 5Advanced Nurse Practitioner, candidate (cANP) (Rapid Access Prostate) in Cork | HSE South Jobs - 4 year(s) ago
HSE South is looking to fill the role of Advanced Nurse Practitioner, candidate (cANP) (Rapid Access Prostate) in Cork. Apply today!
Source: www.rezoomo.comCategories: Latest Headlines, Oncologists1Tweet-
RT @CorpHRSouth: Job Opportunity: Advanced Nurse Practitioner, candidate (cANP) (Rapid Access Prostate) https://t.co/tSmUGgiWU9 @CUH_Cork @…
-
-
Mashup Score: 5Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) - 4 year(s) ago
Purpose: Epigenetic modulators improve immune checkpoint inhibitor (ICI) efficacy and increase CD8+ effector: FoxP3+ regulatory T cell ratios in preclinical models. We conducted a multicenter phase I clinical trial combining the histone deacetylase (HDAC) inhibitor entinostat with nivolumab {plus minus} ipilimumab in advanced solid tumors. Experimental Design: Patients received an entinostat…
Source: Clinical Cancer ResearchCategories: Latest Headlines, Oncologists1Tweet-
Novel combinations to overcome resistance to #immunotherapy urgently required to improve patient outcome. This phase 1 trial bridges areas of expertise @hopkinskimmel- #epigenetics #immunotherapy #clinicaltrials. https://t.co/X0mVgB8jka
-
-
Mashup Score: 1Inhibitor Drug Entinostat ‘Primes’ the Body to Better Respond to Anti-Cancer Treatment with Immunotherapy - 4 year(s) ago
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of…
Source: Johns Hopkins Medicine NewsroomCategories: Latest Headlines, Oncologists1Tweet-
Congratulations @RoussosTorres for getting this over the line! Thanks to @VeredStearns @DrLizJaffee @NCICTEP_ClinRes @UPMCHillmanCC @YaleCancer @cityofhope @bloombergkimmel funding bodies and many others for support. https://t.co/Uom3FTyIkC
-
“How strong is our commitment to supporting the successor generation and to ensuring a critical supply chain of physician-scientists that is agile and sustainable?” A call to action @RCPI_news @UCCMedHealth https://t.co/2ZloEKEFVx